Recombinant CXCL12, specifically purified monomeric CXCL12 (32, 62, 64), has demonstrated its protective effects against myocardial infarction during ischemia/reperfusion injury (27, 31, 32, 65–69). Here, CXCL12 is linked to myocardial infarction.